Subscribe to RSS
DOI: 10.1055/s-2003-37290
Management der hochgradigen Neoplasie der Barrett-Schleimhaut (High Grade Dysplasia)
Management of Barrett's Esophagus with High-Grade DysplasiaPublication History
Publication Date:
18 February 2003 (online)
![](https://www.thieme-connect.de/media/viszeralchirurgie/200301/lookinside/thumbnails/10.1055-s-2003-37290-1.jpg)
Zusammenfassung
Die hochgradige Neoplasie der Barrett-Schleimhaut (HGD) ist definiert als eine intraepitheliale Neoplasie im Rahmen der Metaplasie-Dysplasie-Karzinom-Sequenz des Barrett-Karzinoms. Der natürliche zeitliche Verlauf der malignen Entartung der HGD ist unbekannt, so dass Aussagen zum Risiko der Entwicklung eines invasiven Karzinoms nur eingeschränkt möglich sind. Das zentrale Problem der Behandlung der HGD liegt in den bisher nur unvollkommenen endoskopischen und histopathologischen Nachweismöglichkeiten, die die Sicherung der HGD innerhalb einer Barrett-Metaplasie erschweren. Trotz erheblicher Fortschritte bei der endoskopischen Identifikation der Läsionen sowie verbesserter Nachweisverfahren auf histologischer Ebene bleibt die Diagnostik der HGD kontrovers. Die prognostischen und diagnostischen Unsicherheiten spiegeln sich in der Breite der zur Verfügung stehenden therapeutischen Optionen wider. Diese reichen von regelmäßiger endoskopischer Kontrolle über Ablationsverfahren bis hin zur komplexen thorakoabdominalen Ösophagusresektion. In der vorliegenden Arbeit werden aktuelle diagnostische und therapeutische Strategien zusammenfasst und ein Algorithmus zur Behandlung der HGD erarbeitet.
Abstract
High-grade neoplasia of Barrett's esophagus (HGD) is defined as an intraepithelial neoplastic condition occurring within the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's carcinoma. As the natural history of HGD remains unknown, a patient's actual risk for the development of invasive malignancy is difficult to define. Main drawbacks of the management of HGD are the shortcomings of the endoscopic and histologic diagnostic tools. Despite recent advances of diagnostic tests, the identification of HGD remains controversial. Diagnostic and prognostic uncertainties are reflected by the multitude of therapeutic options that range from endosocopic surveillance to complex thoracoabdominal surgery. The present paper resumes actual diagnostic and therapeutic strategies, an algorithm for the treatment of HGD is proposed by the authors.
Schlüsselwörter
Ösophagus - Barrett-Mukosa - Dysplasie - intraepitheliale Neoplasie
Key words
Esophagus - Barrett's - dysplasia - intraepithelial neoplasia
Literatur
- 1 Sampliner R E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1998; 93 1028-1032
- 2 Hameeteman W, Tytgat G NJ, Houthoff H J, van den Tweel J G. Barrett's esophagus: Development of dysplasia and adenocarcinoma. Gastroenterology. 1989; 96 1249-1256
- 3 Pera M, Trastek V F, Carpenter H A, Allen M S, Descamps C, Pairolero P C. Barrett's esophagus with high-grade dysplasia: an indication for esophagectomy?. Ann Thorac Surg. 1992; 54 199-204
- 4 Reid B J, Weinstein W M, Lewin K J. et al . Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology. 1988; 94 81-90
- 5 Riddell R J. Premalignant and early malignant lesions in the gastrointestinal tract: definitions, terminology, and problems. Am J Gastroenterol. 1996; 91 864-871
- 6 Schlemper R J, Riddell R H, Kato Y. et al . The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000; 47 251-255
- 7 Reid B J, Blount P I, Rubin C E, Levine D S, Haggitt R C, Rabinovitch P S. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: a prospective endoscopic surveillance of a cohort. Gastroenterology. 1992; 102 1212-1219
- 8 Schnell T G, Sontag S J, Chejfec G, Aranha G, Metz A, O'Connell S, Seidel U J, Sonnenberg A. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology. 2001; 120 1607-1619
- 9 Reid B J, Levine D S, Longton G, Blount P L, Rabinovitch P S. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000; 95 1669-1676
- 10 Weston A P, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol. 2000; 95 1888-1893
- 11 Kim S L, Waring J P, Spechler S J, Sampliner R E, Doos W G, Krol W F, Williford W O. Diagnostic inconsistencies in Barrett's esophagus. Gastroenterology. 1994; 107 945-949
- 12 Collard J M. High-grade dysplasia in Barrett's esophagus. The case for esophagectomy. Chest Surg Clin N Am. 2002; 12 77-92
- 13 Canto M I, Yoshida T, Gossner L. Chromoscopy of intestinal metaplasia in Barrett's esophagus. Endoscopy. 2002; 34 330-336
- 14 Bourg-Heckly G, Blais J, Padilla J J, Bourdon O, Etienne J, Guillemin F, Lafay L. Endoscopic ultraviolet-induced autofluorescence spectroscopy of the esophagus: tissue characterization and potential for early cancer diagnosis. Endoscopy. 2000; 32 756-765
- 15 Brand S, Poneros J M, Bouma B E, Tearney G J, Compton C C, Nishioka N S. Optical coherence tomography in the gastrointestinal tract. Endoscopy. 2000; 32 796-803
- 16 Jäckle S, Gladkova N, Feldchtein F, Terentieva A, Brand B, Gelikonov G, Gelikonov V, Sergeev A, Fritscher-Ravens A, Freund J, Seitz U, Schröder S, Soehendra N. In vivo endoscopic optical coherence tomography of esophagitis, Barrett's esophagus, and adenocarcinoma of the esophagus. Endoscopy. 2000; 32 750-755
- 17 Georgakoudi I, Jacobson B C, van Dam J, Backman V, Wallace M B, Müller M G, Zhang Q, Badizadegan K, Sun D, Thomas G A, Perelman L T, Feld M S. Fluorescence, Reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients with Barrett's esophagus. Gastroenterology. 2001; 120 1620-1629
- 18 Wickramasinghe K S, Chandrasoma P T, Chandraratna P A. Detection of Barret's epithelium by acoustic microscopy. Ultrasound Med Biol. 2002; 28 203-207
-
19 Geboes K.
Is it possible to make the unequivocal diagnosis of dysplasia, especially low-grade dysplasia in Barrett's mucosa? . In: Giuli R, Galmiche JP, Jamieson GG, Scarpignato C (eds) The Esophagogastric Junction. Paris; John Libbey 1998: 1081-1084 - 20 Montgomery E, Bronner M P, Goldblum J R, Greenson J K, Haber M M, Hart J, Lamps L W, Lauwers G Y, Lazenby A J, Lewin D N, Robert M E, Toledano A Y, Shyr Y, Washington K. Reproducibility of the diagnosis of dysplasia in Barrett's esophagus: a reaffirmation. Hum Path. 2001; 32 368-378
- 21 Skacel M, Petras R E, Gramlich T L, Sigel J E, Richter J E, Goldblum J R. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implication for disease progression. Am J Gastroenterol. 2000; 95 3383-3387
- 22 Krishnadat K K, Reid B J, Wang K K. Biomarkers in Barrett's esophagus. Maye Clin Proc. 2001; 76 438-446
- 23 Ransford R AJ, Jankowski J AZ. Genetic versus evnironmental interactions in the esophagitis-metaplasia-dysplasia-adenocarcinoma sequenc eof Barrett's esophagus. Acta Gastroenterol Bel. 2000; 63 18-21
- 24 Ell C, May A, Gossner L, Pech O, Günter E, Mayer G, Henrich R, Vieth M, Müller H, Seitz G, Stolte M. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology. 2000; 118 670-677
- 25 Gossner L, Stolte M, Sroka R, Rick K, May A, Hahn E G, Ell C. Photodynamic ablation of high-grade dysplasia and early cance rin Barrett's esophagus by means of 5-aminolaevulinic acid. Gastroenterology. 1998; 114 448-455
- 26 Barr H, Shepherd N A, Dix A, Roberts D J, Tan W C, Krasner N. Eradication of high-grade dysplasi ain columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet. 1996; 348 584-585
- 27 Gossner L, May A, Sroka R, Stolte M, Hahn E G, Ell C. Photodynamic destruction of high grade dysplasia and early carcinoma of the esophagus after the oral administration of 5-aminolevulinic acid. Cancer. 1999; 86 1921-1928
- 28 Panjehpour M, Overholt B F, Haydek J M, Lee S G. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation. Am J Gastroenterol. 2000; 95 2177-2184
- 29 Wang K K. Photodynamic therapy of Barrett's esophagus. Gastrointest Endosc Clin N Am. 2000; 10 409-419
- 30 Klingenberg-Knoll E C, Festen H PM, Jansen J BMJ. et al . Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Int Med. 1994; 121 161-167
- 31 Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol. 1998; 93 711-716
- 32 Stein H J, Kauer W K, Feussner H. et al . Bile reflux in benign andmalignant Barrett's esophagus: effect of medical acid suppression and Nissen fundoplication. J Gastrointest Surg. 1998; 2 333-341
- 33 Akiyama H, Tsurumaru M, Udagawa H, Ono Y, Kajiyama Y. Esophagectomy without thoracotomy with vagal preservation. J Am Coll Surg. 1994; 178 83-85
- 34 DeMeester S R, DeMeester T R. Columnar mucosa and intestinal metaplasi aof the esophagus. Fifty years of controversy. Ann Surg. 2000; 231 303-321
-
35 Collard J M.
The Stomach as an esophageal Substitute after total or subtotal Esophagectomy. Brüssel; Habilitationsschrift 1997: 62-63 - 36 Hölscher A H, Bollschweiler E, Myazono F, Gutschow C, Schäfer H, Schröder W. In: Imamura M (ed) Superficial esophageal neoplasm. Tokyo; Springer 2002: 45-53
- 37 Stein H J, Feith M, Mueller J, Werner M, Siewert J R. Limited resection for early adenocarcinoma in Barrett's esophagus. Ann Surg. 2000; 232 773-742
- 38 Hölscher A H, Bollschweiler E, Schneider P M, Siewert J R. Early adenocarcinoma in Barrett's esophagus. Br J Surg. 1997; 84 1470-1473
Dr. med. Christian A. Gutschow
Klinik und Poliklinik für Viszeral- und Gefäßchirurgie, Universität zu Köln
Joseph-Stelzmann-Straße 9
50931 Köln
Phone: + 49-221-478-4803
Fax: + 49-221-478-6258
Email: ch.gutschow@t-online.de